Hologic Inc (OQ:HOLX)

Business Focus: Advanced Medical Equipment & Technology

Apr 02, 2024 08:08 am ET
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2024 on Thursday, May 2, 2024
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2024 on Thursday, May 2, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Mar 05, 2024 08:10 am ET
Newly Published Results Reveal a Significant Proportion of Early-Stage HR+ Breast Cancer Survivors May Be Over- or Undertreated Without Breast Cancer Index Genomic Testing
Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced newly published study results revealing that use of the Breast Cancer Index® (BCI) test led to physicians changing their long-term anti-estrogen treatment recommendations for 40% of patients with early-stage hormone receptor-positive (HR+) breast cancer.1 The results, which suggest that many women may be over- or undertreated without the incorporation of BCI, reflect real-world data from the largest prospective study assessing the impact of the BCI test on treatment decisions. The stud
Feb 27, 2024 08:00 am ET
Hologic to Unveil Groundbreaking AI Research at ECR 2024
Hologic, Inc. (Nasdaq: HOLX) continues to deliver on its commitment to advancing women’s health by unveiling new research in artificial intelligence (AI) and offering innovative educational opportunities at the annual European Congress of Radiology (ECR) in Vienna, Austria from February 28 to March 2.
Feb 26, 2024 04:15 pm ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:
Feb 01, 2024 05:35 pm ET
Hologic Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System
Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System with the Genius™ Cervical AI algorithm has received clearance from the U.S. Food and Drug Administration (FDA), making it the first and only FDA-cleared digital cytology system that combines deep-learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells.
Feb 01, 2024 04:01 pm ET
Hologic Announces Financial Results for First Quarter of Fiscal 2024
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 30, 2023.
Jan 16, 2024 08:30 am ET
Women's Health Remains in Crisis Worldwide Even as COVID-19 Pandemic Wanes
The world faces an emergency in women’s health even as the COVID-19 pandemic wanes, according to one of the largest annual updates on women’s well-being — the Hologic Global Women’s Health Index.
Jan 11, 2024 08:08 am ET
Hologic Launches ‘Better Is Possible’ Health Awareness Campaign for Women
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced its new uterine health education and awareness campaign Better is Possible™. Launching in New York, Los Angeles, Atlanta and Detroit, the campaign seeks to increase awareness about daily quality-of-life challenges such as heavy and disruptive periods, pelvic pain and fibroids, while also educating women about available treatment options.
Jan 07, 2024 04:00 pm ET
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2024
Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 30, 2023.
Jan 04, 2024 08:33 am ET
Hologic to Announce Financial Results for the First Quarter of Fiscal 2024 on Thursday, February 1, 2024
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2024 on Thursday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Jan 02, 2024 08:08 am ET
Hologic to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 1:30 p.m. Pacific Time.
Nov 30, 2023 06:00 am ET
KKR, Hologic and Ajax Health Create New Platform to Accelerate Medical Device Innovation
KKR, a leading global investment firm, today announced a new platform established with investments from KKR and Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health and medical technology innovator. The new platform, named Maverix Medical, will be managed by Ajax Health under the leadership of Duke Rohlen.
Nov 24, 2023 08:05 am ET
Hologic to Showcase Developments in Next-Generation AI Solutions at RSNA 2023
Hologic, Inc. (Nasdaq: HOLX) will showcase several recent developments in next-generation AI solutions at the 109th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 26 to 30. On the show floor and during multiple workshops, the global leader in breast imaging will unveil advances that leverage AI to improve cancer detection, workflow and patient satisfaction.
Nov 21, 2023 08:15 am ET
Hologic to Webcast Presentation at the 6th Annual Evercore ISI HealthCONx Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 2:10 p.m. Eastern Time.
Nov 09, 2023 04:01 pm ET
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2023
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 30, 2023.
Oct 10, 2023 08:30 am ET
Hologic Announces Innovative Collaboration with AAGL and Inovus Medical to Optimize OB-GYN Training for Minimally Invasive Surgeries
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced an innovative new partnership with the American Association of Gynecologic Laparoscopists (AAGL) and Inovus Medical. Hologic becomes the chief provider of hysteroscopes for AAGL’s Essentials in Minimally Invasive Gynecologic Surgery (EMIGS) hands-on hysteroscopy skills training for OB-GYN residents.
Oct 05, 2023 08:00 am ET
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2023 on Thursday, November 9, 2023
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2023 on Thursday, November 9, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Sep 29, 2023 08:00 am ET
Hologic to Expand Outreach During Breast Cancer Awareness Month
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced a series of activities promoting the importance of breast cancer screenings throughout Breast Cancer Awareness Month, including a global partnership with Know Your Lemons, a nonprofit organization committed to improving early detection of breast cancer worldwide through creative and empowering education. To kick off the month, Hologic Chairman, President and CEO Steve MacMillan will ring the Nasdaq opening bell on Monday, October 2, with Hologic employees as well as tennis legend and two-time breast cancer survivo
Sep 22, 2023 08:00 am ET
Nanaz Mohtashami Elected to Hologic Board of Directors
Hologic, Inc. (Nasdaq: HOLX) announced today that Nanaz Mohtashami has been elected to the Company’s Board of Directors, effective September 20, 2023. Ms. Mohtashami was also appointed to the Compensation Committee and the Nominating and Corporate Governance Committee effective September 20, 2023.
Sep 21, 2023 08:30 am ET
Hologic and Bayer Announce International Partnership to Deliver Comprehensive Contrast-Enhanced Mammography Package to Breast Imaging Facilities
Hologic Inc. (Nasdaq: HOLX) and Bayer today announced an international partnership to deliver contrast-enhanced mammography (CEM) solutions to improve the detection of breast cancer for women in multiple countries across the European, Canadian and Asia Pacific regions.
Sep 11, 2023 07:30 am ET
Jennifer Meade Named President at Aldevron
FARGO, N.D., Sept. 11, 2023 /PRNewswire/ -- Jennifer Meade has been named President of Aldevron, effective September 11th 2023, as part of a planned leadership transition. She replaces Kevin Ballinger, who has departed Aldevron after leading the organization for three years.
Aug 30, 2023 08:00 am ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:
Jul 31, 2023 04:01 pm ET
Hologic Announces Financial Results for Third Quarter of Fiscal 2023
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended July 1, 2023.
Jul 05, 2023 08:08 am ET
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2023 on Monday, July 31, 2023
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2023 on Monday, July 31, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
May 19, 2023 08:08 am ET
Hologic Announces FDA Clearance of Panther Fusion SARS-CoV-2/Flu A/B/RSV Assay
Hologic Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay. This assay is a molecular diagnostic test that detects and differentiates four of the most prevalent respiratory viruses that can exhibit similar clinical symptoms: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A (flu A), influenza B (flu B) and respiratory syncytial virus (RSV).
May 16, 2023 09:12 am ET
Hologic Announces Partnership with NFL Rookie Kelee Ringo and Family
MARLBOROUGH, Mass., May 16, 2023 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced a new partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale, to educate women on the importance of prioritizing annual mammograms and other key health screenings.
May 08, 2023 08:00 am ET
Hologic Announces Partnership with NFL Rookie Kelee Ringo and Family
Hologic Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced a partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale, to educate women on the importance of prioritizing annual mammograms and other key health screenings.
May 02, 2023 04:02 pm ET
Hologic to Webcast Presentation at the BofA Securities 2023 Healthcare Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the BofA Securities 2023 Healthcare Conference in Las Vegas, NV on Tuesday, May 9 at 2:20 p.m. Pacific Time.
May 01, 2023 04:02 pm ET
Hologic Announces Financial Results for Second Quarter of Fiscal 2023
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended April 1, 2023.
Apr 03, 2023 04:04 pm ET
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2023 on Monday, May 1, 2023
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2023 on Monday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Feb 28, 2023 08:08 am ET
Hologic to Webcast Presentation at the Cowen 43rd Annual Health Care Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7 at 9:10 a.m. Eastern Time (E.T.)
Feb 21, 2023 04:02 pm ET
Hologic “Making a World of Difference” Through Global Sustainability Impact
Hologic, Inc. (Nasdaq: HOLX) announced today the publishing of “Making a World of Difference,” its latest annual report detailing the company’s sustainability strategy and achievements.
Feb 17, 2023 08:08 am ET
Court of Appeals Affirms District Court Decision Invalidating Minerva Surgical Patent
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit unanimously affirmed a 2021 district court ruling that invalidated a Minerva patent asserted against Hologic. The appellate court ruled that Minerva’s patent is invalid because it waited more than a year to file a patent application after showing a prototype of the invention at a trade show.
Feb 15, 2023 08:00 am ET
NovaSure® V5 Global Endometrial Ablation Device Approved for Use in Canada and Europe
Hologic Inc. (Nasdaq: HOLX), a global leader in women's health, has announced approval of the NovaSure® V5 global endometrial ablation (GEA) device in Canada and Europe. This innovative new version incorporates enhanced features designed to treat a wide range of cervical and uterine anatomies. It builds on a world-class track record for NovaSure, including 3 million patients who have benefited from the device.
Feb 01, 2023 04:01 pm ET
Hologic Announces Financial Results for First Quarter of Fiscal 2023
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 31, 2022.
Jan 08, 2023 04:00 pm ET
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2023
Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 31, 2022.
Jan 03, 2023 08:08 am ET
Hologic to Announce Financial Results for the First Quarter of Fiscal 2023 on Wednesday, February 1, 2023
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2023 on Wednesday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Dec 27, 2022 04:02 pm ET
Hologic to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. Pacific Time.
Dec 09, 2022 04:15 pm ET
Stacey D. Stewart Elected to Hologic Board of Directors
Hologic, Inc. (Nasdaq: HOLX) announced today that Stacey D. Stewart has been elected to the Company’s Board of Directors, effective January 2, 2023. Ms. Stewart was also appointed to the Audit and Finance Committee effective January 2, 2023.
Dec 06, 2022 04:04 pm ET
New Data Presented at SABCS 2022 Reveal Expanded Predictive Value of the Breast Cancer Index™ Test for Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer
Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new study data showing that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive (HR+) breast cancer benefited from the addition of ovarian function suppression (OFS) to primary adjuvant endocrine therapy. The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the landmark Suppression of Ovarian Function Trial (SOFT). The translational study results are featured in the official press program at the 2022 San Antonio Bre
Dec 01, 2022 08:05 am ET
Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, swept the 2022 IMV ServiceTrak™ Awards for Mammography, taking home awards for Best Service, Best Customer Satisfaction and Best System Performance. This is the 10th consecutive year that Hologic has ranked first in the industry for Mammography System Performance and Customer Satisfaction and the eighth year for Mammography Service.
Nov 25, 2022 08:08 am ET
Hologic to Showcase Portfolio of Comprehensive Breast and Skeletal Health Solutions at RSNA 2022
Hologic, Inc. (Nasdaq: HOLX) will exhibit its extensive portfolio of breast and skeletal health products at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec. 1. Among the full suite of breast biopsy and surgery solutions will be Hologic’s Affirm® Contrast Biopsy software, which will be on display for the first time since becoming commercially available in the United States.
Nov 22, 2022 08:22 am ET
Hologic to Webcast Presentation at the 5th Annual Evercore ISI HealthCONx Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 2:40 p.m. Eastern Time.
Nov 03, 2022 08:00 am ET
Hologic’s 3Dimensions™ System for 3D Mammography Receives EUREF Type Test Certification
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that its 3Dimensions™ mammography system was awarded EUREF Type Test certification by the European Reference Organisation for Quality Assured Breast Screening and Diagnostic Services (www.EUREF.org).1 It is the first digital breast tomosynthesis (DBT) system to receive
Nov 02, 2022 08:02 am ET
Hologic Announces Contract with BARDA to Support IVD Approval of COVID Assays
Hologic, Inc. (Nasdaq: HOLX) announced today that it has been awarded a $19 million contract from the Biomedical Advanced Research and Development Authority (BARDA) to support research and development efforts. This funding will help to bring Hologic’s Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and Aptima® SARS-CoV-2 assay in line with the U.S. Food and Drug Administration’s (FDA) in vitro diagnostic (IVD) standards.
Nov 01, 2022 09:31 am ET
Thinking about trading options or stock in Alibaba, Hologic, Imperial Oil, Wynn Resorts, or BioNTech?
NEW YORK, Nov. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BABA, HOLX, IMO, WYNN, and BNTX.
Oct 31, 2022 04:01 pm ET
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2022
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 24, 2022.
Oct 04, 2022 08:22 am ET
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2022 on Monday, October 31, 2022
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2022 on Monday, October 31, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Oct 03, 2022 08:00 am ET
Hologic Rings Nasdaq Opening Bell to Kick Off Breast Cancer Awareness Month
Hologic, Inc. Chairman, President and CEO Steve MacMillan will ring the Nasdaq opening bell today to mark the beginning of Breast Cancer Awareness Month. This is the 16th time that Hologic (Nasdaq: HOLX), an innovative medical technology company and the pioneer of 3D mammography, will ring the bell to raise awareness about breast cancer.
Sep 21, 2022 07:00 am ET
More than 1.5 Billion Women Worldwide Lack Essential Health Screenings
More than 1.5 billion women worldwide lack screenings for cancer, heart disease, diabetes or sexually transmitted diseases/infections – even though these conditions together affect billions of women. The finding comes from one of the world’s largest studies of women’s well-being: the second annual Hologic Global Women’s Health Index.
Aug 30, 2022 08:08 am ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming investor conferences:
Aug 12, 2022 08:01 am ET
Hologic and Mary J. Blige Launch “Good Morning Gorgeous” Sweepstakes as a Wake-up Call to Increase Awareness of the Importance of Preventive Care
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, and Grammy award-winning and Oscar-nominated artist, producer, and entrepreneur Mary J. Blige today announced the launch of the “Good Morning Gorgeous” sweepstakes. The sweepstakes is an element of Hologic’s role as presenting sponsor of Blige’s “Good Morning Gorgeous” tour, which is presented in partnership with The Black Promoters Collective (BPC) and will take place September 17 through October 29, 2022.
Aug 11, 2022 06:06 pm ET
U.S. Court of Appeals for the Federal Circuit Affirms 2018 Ruling Barring Minerva from Challenging Hologic’s Patent Rights
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva from challenging the validity of the patent rights it assigned to Hologic.
Jul 31, 2022 11:30 pm ET
Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology
CARLSBAD, Calif., July 31, 2022 /CNW/ -- Active Motif Incorporated, a company with the vision of bringing epigenetics more deeply into precision medicine, announced that it has non-exclusively licensed its foundational patents in transposition for use in CUT&Tag epigenetic assays to Diagenode S.A., a Hologic company (NASDAQ: HOLX). The innovations underlying these patents allow mechanistic, translational, and clinical researchers to interrogate open chromatin with the goal of gaining an increased understanding of biological processes.  Through the licensing arrangement, Diagenode gains a
Jul 31, 2022 11:30 pm ET
Active Motif Incorporated Licenses Targeted Transposition to Diagenode S.A. Technology
CARLSBAD, Calif., July 31, 2022 /PRNewswire/ -- Active Motif Incorporated, a company with the vision of bringing epigenetics more deeply into precision medicine, announced that it has non-exclusively licensed its foundational patents in transposition for use in CUT&Tag epigenetic assays to Diagenode S.A., a Hologic company (NASDAQ: HOLX). The innovations underlying these patents allow mechanistic, translational, and clinical researchers to interrogate open chromatin with the goal of gaining an increased understanding of biological processes.  Through the licensing arrangement, Diagenode
Jul 27, 2022 04:02 pm ET
Hologic Announces Financial Results for Third Quarter of Fiscal 2022
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 25, 2022.
Jul 13, 2022 08:00 am ET
Hologic Showcases Advances across the Continuum of Breast Health at ECR 2022
Hologic, Inc. (Nasdaq: HOLX) will showcase their comprehensive portfolio of breast and skeletal health solutions at the annual European Congress of Radiology (ECR) in Vienna, Austria from July 13-17.
Jul 11, 2022 08:00 am ET
Hologic Announces Two New Respiratory Assays for the Detection of COVID-19, Flu A, Flu B and RSV
Hologic, Inc. (Nasdaq: HOLX) announced today that it is now offering its Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay and its Novodiag® RESP-4 molecular diagnostic test for sale in the European Union in time for the northern hemisphere’s respiratory viral season. Both assays detect and differentiate four of the most prevalent respiratory viruses that can present with similar clinical symptoms: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A (Flu A), influenza B (Flu B) and respiratory syncytial virus (RSV).
Jul 05, 2022 04:04 pm ET
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2022 on Wednesday, July 27, 2022
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2022 on Wednesday, July 27, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Jul 01, 2022 08:05 am ET
New Survey Reveals Lack of Knowledge among U.S. Women about Uterine Health, Including Fibroid Symptoms and Treatment Options
A new survey commissioned by Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, revealed a lack of awareness among U.S. women about uterine health, including uterine fibroid symptoms and treatment options. Today, in conjunction with the start of Fibroid Awareness Month, Hologic is proud to announce the launch of Hey, U!, an educational campaign focused on uterine health.
May 25, 2022 08:02 am ET
Hologic Announces European CE Mark for Molecular Assays for Use with Transplant Patients
The assays are in vitro nucleic acid amplification tests (NAAT) that are run on the fully automated Panther Fusion system using real-time Polymerase Chain Reaction (PCR) technology. The Panther Fusion EBV Quant is validated for use with whole blood and plasma samples. The Panther Fusion BKV Quant is validated for use with human plasma and urine samples. Plasma, whole blood and urine specimens are important biomarkers when using quantitative NAATs for diagnosis and management of transplant patients. It is crucial that viral levels are accurately quantitated in transplant recipients to gu
May 17, 2022 08:15 am ET
Hologic Board Member, Sally W. Crawford, Recognized As NACD Directorship 100™ Honoree
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that Board of Director's member, Sally W. Crawford, has been recognized by the National Association of Corporate Directors (NACD) as part of its 2022 NACD Directorship 100™ — honoring the most influential peer-nominated leaders in the boardro
May 10, 2022 04:02 pm ET
Hologic Announces FDA Approval of Aptima® CMV Quant Assay for Human Cytomegalovirus
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) approved its Aptima CMV Quant assay to quantify the viral load of cytomegalovirus (CMV) in patients who have had solid organ or stem cell transplants. The test is the first to be introduced in the U.S. by Hologic for post-transplant pathogen detection and monitoring on Hologic’s fully automated Panther® system, and joins the existing portfolio of diagnostic and viral load testing for HIV-1, Hepatitis C and Hepatitis B.
May 04, 2022 08:30 am ET
Hologic to Webcast Presentation at Upcoming Investor Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:
Apr 27, 2022 04:01 pm ET
Hologic Announces Financial Results for Second Quarter of Fiscal 2022
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 26, 2022.
Apr 25, 2022 08:08 am ET
American Society of Clinical Oncology (ASCO) Clinical Practice Guideline Now Includes Breast Cancer Index™ to Guide Decisions about Extended Endocrine Therapy
Hologic, Inc. (Nasdaq: HOLX) announced today that the American Society of Clinical Oncology (ASCO) has published an update which expands the utility of Breast Cancer Index™ (BCI) within its Clinical Practice Guideline: “Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer.” Specifically, ASCO now recognizes BCI as the only genomic test to help guide extended endocrine therapy decisions in early-stage, HR+ breast cancer patients with node negative or node positive (one-three positive nodes) disease when treated with five years of primary endocrine
Apr 04, 2022 04:01 pm ET
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2022 on Wednesday, April 27, 2022
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2022 on Wednesday, April 27, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Mar 09, 2022 08:00 am ET
Hologic WTA Tour Swings into Action Ahead of BNP Paribas Open
Hologic and the WTA kicked off a multi-year partnership this week with their first onsite activities at the BNP Paribas Open in Indian Wells, launching a joint vision to achieve greater wellness and equality for women. The Hologic WTA Tour was announced last week when medical technology leader Hologic became the title sponsor for the WTA, the global leader in women’s professional sports.
Mar 03, 2022 07:00 am ET
Hologic Partners With the WTA Tour in Landmark Title Sponsorship
The WTA and Hologic today jointly announced a landmark partnership introducing Hologic as the global title sponsor of the WTA Tour.
Feb 15, 2022 04:05 pm ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the following upcoming investor conferences:
Feb 02, 2022 04:01 pm ET
Hologic Announces Financial Results for First Quarter of Fiscal 2022
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 25, 2021.
Feb 01, 2022 07:00 am ET
Hologic Launches First-Ever National Advertising Campaign Featuring Mary J. Blige
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, announced today the details of its first national, direct-to-consumer advertising campaign. The campaign will launch with a 30-second spot on NBC during the “Big Game” on February 13, 2022, and run through the Winter Olympics across NBCU television and digital channels.
Jan 24, 2022 08:08 am ET
Hologic’s Sustainability Leadership Makes Company “A Global Force for Good”
Hologic, Inc. (Nasdaq: HOLX) announced today the online publication of “A Global Force for Good,” a report detailing the Company’s environmental, social and governance (ESG) achievements in 2021.
Jan 09, 2022 04:00 pm ET
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2022
Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 25, 2021.
Jan 05, 2022 04:05 pm ET
Hologic to Announce Financial Results for the First Quarter of Fiscal 2022 on Wednesday, February 2, 2022
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2022 on Wednesday, February 2, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Jan 05, 2022 08:00 am ET
Hologic Adds Aptima SARS-CoV-2 Assay to its Global Access Initiative in Resource-Limited Countries
Hologic, Inc. (NASDAQ: HOLX) announces the addition of the Aptima® SARS-CoV-2 assay to its Global Access Initiative (GAI), a program designed to expand access to critical diagnostic testing in resource-limited countries.
Dec 28, 2021 08:15 am ET
Hologic to Webcast Presentation at the 40th Annual J.P. Morgan Healthcare Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 1:30 p.m. Eastern Time.
Dec 23, 2021 08:08 am ET
Hologic Launches Panther Trax for High Volume Molecular Testing
Hologic (Nasdaq: HOLX) announced today that it has completed regulatory filings needed to make Panther Trax® available in a number of countries and regions. Launch of Panther Trax represents the latest addition to the Panther® Scalable Solutions (PSS) portfolio of products, offering the ultimate in lab automation by physically linking multiple Panther instruments together into a single, powerful workcell that allows labs to increase testing volumes without increasing staff.
Dec 10, 2021 08:05 am ET
Hologic Presents Breast Cancer Index™ Data at SABCS 2021 Showing Net Benefit Predictive Value for Endocrine Therapy Continuation
Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating that Breast Cancer Index™ (BCI) not only predicts preferential recurrence-prevention benefit from extended endocrine therapy (EET), but also predicts the overall benefit/risk and likelihood of improved health outcomes from EET in certain hormone receptor positive (HR+) patients. New data also confirm two biomarkers used in BCI are interconnected molecular drivers of assessing recurrences in HR+ breast cancer. These findings were presented in Spotlight Sessions at the 2021 San Antonio
Nov 30, 2021 09:00 am ET
Hologic Closes on Acquisition of Bolder Surgical
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced acquisition of Bolder Surgical, a privately held, U.S.-based company that provides advanced energy vessel sealing surgical devices.
Nov 30, 2021 08:02 am ET
Hologic Pledges to Donate $5 Million to Improve Women’s Health, STEM Education and Social Justice
Hologic, Inc. (Nasdaq: HOLX), a global leader in medical technology with a primary focus on improving women’s health, announced on Giving Tuesday that it will expand its philanthropic efforts with $5 million in donations to nonprofit organizations located near its major facilities over the coming year.
Nov 29, 2021 08:26 pm ET
Hologic’s COVID-19 Tests Detect Omicron Variant
Hologic, Inc. (Nasdaq: HOLX) announced today that its three SARS-CoV-2 tests all detect the recently emerged Omicron variant of the coronavirus that causes COVID-19. Initially identified in South Africa and subsequently in a number of African, European and North American countries, the Omicron variant (B.1.1.529) contains approximately 30 mutations.
Nov 23, 2021 08:05 am ET
Hologic to Host Innovative Product Experiences and Medical Education Sessions On-site and Virtually at RSNA 2021
Hologic, Inc. (Nasdaq: HOLX) will showcase its extensive portfolio of breast and skeletal health products, including screening and diagnostics solutions, breast biopsy, and breast cancer treatment and monitoring solutions, at the 107th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 28 to Dec. 2.
Nov 22, 2021 04:04 pm ET
Hologic to Webcast Presentation at Upcoming Virtual Investor Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 4th Annual Evercore ISI HealthCONx Conference on Tuesday, November 30 at 9:40 a.m. Eastern Time.
Nov 18, 2021 11:15 am ET
Canada Ranks 43 out of 116 Countries and Territories on Women's Health
 Hologic Launches Canadian Results of Inaugural Global Women's Health Index
Nov 04, 2021 04:00 am ET
Hologic Announces European Launch of Genius™ Digital Diagnostics System for Cervical Cancer Screening
Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System is now commercially available in Europe. The Genius Digital Diagnostics System is the next generation of cervical cancer screening that combines deep learning-based artificial intelligence (AI) with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells in women. It was developed to provide actionable insights, and improve workflow and lab efficiency, all with one goal in mind – to eradicate cervical cancer.
Nov 02, 2021 08:08 am ET
Hologic to Launch the NovaSure® V5 Global Endometrial Ablation Device at Upcoming American Association of Gynecologic Laparoscopists 50th Global Congress
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, will launch the NovaSure® V5 global endometrial ablation (GEA) device at the American Association of Gynecologic Laparoscopists (AAGL) 50th Global Congress on (November 14-17). The most studied and trusted endometrial ablation procedure in the United States, the innovative new NovaSure® V5 device represents Hologic's ongoing commitment to enhance the physician experience.1
Nov 01, 2021 04:01 pm ET
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2021
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 25, 2021.
Oct 27, 2021 04:02 pm ET
Hologic’s Multiplex COVID-19/Flu Test Now Commercially Available in North America and Europe
Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® SARS-CoV-2/Flu Assay is now available for the simultaneous detection and differentiation of three respiratory viruses that can present with overlapping clinical symptoms.
Oct 20, 2021 08:15 am ET
Hologic Debuts Documentary-Style Film Highlighting One Woman's Breast Cancer Journey Timed to Breast Reconstruction Awareness Day
In conjunction with ongoing Breast Cancer Awareness Month efforts, Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, unveiled Carolina, a narrative documentary-style film about the breast cancer journey from diagnosis to reconstruction, developed in collaboration with Mediflix and Moonlight Productions.
Oct 19, 2021 08:00 am ET
Experts Issue a Call-to-Action to Recognize Periods as a Vital Sign of Health to Reduce Disparities in Uterine Fibroid Care for Black Women
A multidisciplinary group of experts agree that elevating awareness of a woman’s period as a vital sign of health would help to routinize and prioritize care for the uterine fibroids that impact eighty percent of Black women1. This approach was one of several key initiatives proposed to reduce disparities in uterine fibroid care during Unmuting Fibroids: Getting Loud for Equal Care, a roundtable convened by The Black Women’s Health Imperative (BWHI) in partnership with Hologic’s
Oct 14, 2021 04:02 pm ET
Hologic to Acquire Bolder Surgical for $160 Million, Expanding its Surgical Franchise
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has signed a definitive agreement to acquire Bolder Surgical, a privately held, U.S.-based company that provides advanced energy vessel sealing surgical devices, for approximately $160 million, subject to working capital and other customary closing adjustments.
Oct 07, 2021 04:05 pm ET
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2021 on Monday, November 1, 2021
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2021 on Monday, November 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Oct 04, 2021 06:00 am ET
Hologic Rings Nasdaq Opening Bell for 15th Time to Kick Off Breast Cancer Awareness Month
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, announced today that CEO Steve MacMillan will ring the Nasdaq opening bell on October 4 to mark the beginning of Breast Cancer Awareness Month.
Sep 30, 2021 08:00 am ET
Hologic Expands its Omni® Hysteroscopy Offering in Europe
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has launched its expanded Omni® suite, a comprehensive gynecological surgical offering designed to optimize diagnostic and operative hysteroscopy, in Europe, Africa and the Middle East (EMEA). The offering now includes a versatile Omni 30° hysteroscope, the Omni Lok cervical seal and the Omni 5 French seal, which complement the company’s existing portfolio of GYN surgical solutions and extend physicians’ choices.
Sep 21, 2021 07:00 am ET
Hologic Releases Results of Inaugural Global Women’s Health Index – First Study Representing the Health of 2.5 Billion Women and Girls
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, today shared the findings from its inaugural Hologic Global Women’s Health Index, the world’s most comprehensive, globally comparative survey about women’s health.
Sep 02, 2021 04:04 pm ET
Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming virtual investor conferences:
Aug 23, 2021 08:05 am ET
Anthem, Nation’s Second Largest Health Plan, Now Covers Hologic’s Acessa Procedure as a Treatment for Uterine Fibroids
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that Anthem Blue Cross Blue Shield, the second largest health plan in the United States, has updated its medical policy to cover Radiofrequency Ablation (LAP-RFA), which includes the Acessa® procedure (CPT Code 58674), for women suffering from uterine fibroids. The updated policy creates access to uterine-preserving care for Anthem’s approximately 40 million members in all 50 states, providing a safe and effective alternative for millions of women who otherwise might have to resort to unwanted hysterectomies.
Jul 28, 2021 04:01 pm ET
Hologic Announces Financial Results for Third Quarter of Fiscal 2021
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 26, 2021.
Jul 26, 2021 08:02 am ET
New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs), Recommend Nucleic Acid Testing for Mycoplasma Genitalium
Hologic, Inc. (Nasdaq: HOLX) commends the decision by the United States Centers for Disease Control and Prevention (CDC) to endorse an updated approach to screening for Chlamydia trachomatis and Neisseria gonorrhoea, two of the most common sexually transmitted infections (STIs) in the country.1 The guidelines state that providers may now consider opt-out screening, sometimes referred to as universal screening, for these infections in adolescent and young adult women during routine clinical care.2 Studies support that opt-out STI testing can imp
Jul 06, 2021 08:15 am ET
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2021 on Wednesday, July 28, 2021
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2021 on Wednesday, July 28, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Jun 23, 2021 02:45 am ET
Hologic Receives European CE Mark for Molecular Assay to Quantify Human Cytomegalovirus
Hologic, Inc. (Nasdaq: HOLX) has received CE mark for its new Aptima® CMV Quant assay in Europe, the Company announced today. This assay, which quantifies the viral load of human cytomegalovirus (CMV), is intended for use to aid in the diagnosis and management of solid-organ transplant patients and hematopoietic stem cell transplant patients. This in vitro nucleic acid amplification test (NAAT) uses real-time transcription-mediated amplification (TMA) technology on the fully automated Panther® system and can be used with human plasma and whole blood samples.
Jun 17, 2021 08:45 am ET
Hologic Completes Acquisition of Mobidiag
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced acquisition of Mobidiag Oy, an innovator in near-patient, acute care molecular diagnostic testing, for an enterprise value of approximately $808 million.
Jun 03, 2021 04:27 pm ET
Cigna Updates Medical Policy to Cover Hologic’s Acessa® Procedure, Expanding Access to Millions of Women Across the Country
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that Cigna, one of the largest global health insurance service companies, has updated its medical policy to cover the Acessa® Laparoscopic Radiofrequency Ablation (Lap-RFA) procedure (CPT code 58674) as medically necessary.
May 24, 2021 08:24 am ET
New Fibroid Management Guidance from the American College of Obstetricians and Gynecologists Supports Laparoscopic Radiofrequency Ablation (Lap-RFA) as a Minimally Invasive, Uterine Preserving Treatme
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that the American College of Obstetricians and Gynecologists (ACOG), in its updated guidance for Management of Symptomatic Uterine L
May 11, 2021 08:03 am ET
Hologic and Partners Launch Project Health Equality to Help Transform the Care Women of Color Receive in the Health Care System
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today launched Project Health Equality (PHE), a unique initiative that strives to address the structural and cultural barriers that prevent Black and Hispanic women in the U.S. from receiving the same quality health care as white women. PHE will focus initially on how health care is experienced by thousands of Black and Hispanic women in regions across the United States. It will leverage crucial partners to make meaningful, sustainable health care improvements in these communities.
May 10, 2021 04:02 pm ET
Medicare Insurance Coverage for Breast Cancer Index™ Test Expanded to Include Node-Positive Breast Cancer
Hologic, Inc. (Nasdaq: HOLX) announced today that its subsidiary, Biotheranostics, Inc., has received broader Medicare coverage for its Breast Cancer Index™ test under an expanded Medicare Local Coverage Determination (LCD: L37822) effective today.
May 04, 2021 07:09 pm ET
Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming virtual investor conferences:
Apr 28, 2021 04:01 pm ET
Hologic Announces Financial Results for Second Quarter of Fiscal 2021
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 27, 2021.
Apr 08, 2021 08:00 am ET
Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has signed a definitive agreement to acquire Mobidiag Oy, a privately held, commercial-stage Finnish-French developer of innovative molecular diagnostic tests and instrumentation, for an enterprise value of approximately $795 million. This includes a cash payment of approximately $714 million (€600 million) for Mobidiag’s equity, and net debt of approximately $81 million.
Apr 07, 2021 08:08 am ET
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2021 on Wednesday, April 28, 2021
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2021 on Wednesday, April 28, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Mar 22, 2021 08:03 am ET
Hologic Receives Gallup Exceptional Workplace Award
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has been named a winner of the 2021 Gallup Exceptional Workplace Award, the Company announced today. This prestigious award recognizes the most engaged workplace cultures in the world.
Mar 16, 2021 10:23 am ET
CEO’s of Hologic, Empower Clinics, Oak Street Health, and Reliq Health Technologies - Positioning For Post-Pandemic Healthcare Boom Ahead
Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Hologic (NASDAQ: HOLX) Empower Clinics (OTC: EPWCF) (CSE: CBDT), Oak Street Health (NYSE: OSH), Reliq...
Mar 08, 2021 08:01 am ET
Hologic Announces Multi-year Initiative to Improve Quality of Life and Life Expectancy of Women Worldwide
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, today announced a collaboration with leading analytics and consulting firm Gallup, Inc. on the creation of the Hologic Global Women’s Health Index, the largest and most comprehensive assessment of women’s health in the world.
Mar 01, 2021 07:00 am ET
Hologic Acquires European Molecular Diagnostic Company Diagenode for Approximately $159 Million
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has acquired Diagenode, a privately held, European developer and manufacturer of molecular diagnostic assays and epigenetics products, for approximately $159 million (130 million euros), subject to working capital and other customary closing adjustments.
Feb 22, 2021 04:02 pm ET
Hologic Completes Acquisition of Biotheranostics, Enabling Entry into Growing Oncology Market
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, has completed its previously announced acquisition of molecular oncology leader Biotheranostics, Inc.
Feb 19, 2021 05:30 am ET
New Research Published in the Journal of the American College of Radiology Confirms Black Women More Likely to Receive Inferior Breast Cancer Screening Than White Women, Points to Need for Stronger Br
A comprehensive study published in the Journal of the American College of Radiology (JACR) found racial disparities in the utilization of mammography screening overall, and specifically for digital breast tomosynthesis (DBT).
Feb 11, 2021 07:00 am ET
AMETEK Announces Appointment of Karleen Oberton to Board of Directors
BERWYN, Pa., Feb. 11, 2021 /PRNewswire/ -- AMETEK, Inc. (NYSE: AME) today announced that its Board of Directors has appointed Karleen Oberton as a new director of the Company. Ms. Oberton serves as Chief Financial Officer of Hologic, Inc. (NASDAQ: HOLX), an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment systems.
Feb 10, 2021 04:05 pm ET
Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming virtual investor conferences:
Feb 04, 2021 08:08 am ET
Hologic’s New Sustainability Report Highlights How the Company’s Purpose-Driven Culture is Making a Unique Difference in the World
Hologic, Inc. (Nasdaq: HOLX) announced today the on-line publication of its 2020 sustainability report, “The Power of Purpose.”
Feb 01, 2021 04:01 pm ET
Hologic and Google Cloud Announce Collaboration to Advance Next Generation Digital Diagnostic Capabilities
Hologic, Inc. (Nasdaq: HOLX) announced today a multi-year strategic collaboration with Google Cloud that will feature the integration of Google Cloud’s machine learning (ML) technologies with Hologic’s cutting-edge
Jan 27, 2021 04:01 pm ET
Hologic Announces Financial Results for First Quarter of Fiscal 2021
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 26, 2020.
Jan 08, 2021 09:00 am ET
Hologic to Announce Financial Results for the First Quarter of Fiscal 2021 on Wednesday, January 27, 2021
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2021 on Wednesday, January 27, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Jan 08, 2021 08:30 am ET
Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2021
Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 26, 2020.
Jan 05, 2021 04:01 pm ET
Hologic to Acquire Biotheranostics, Leader in Molecular Tests for Breast and Metastatic Cancers, for Approximately $230 Million
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has agreed to acquire Biotheranostics, Inc., a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers, for approximately $230 million, subject to working capital and other customary closing adjustments.
Jan 04, 2021 08:05 am ET
Hologic to Acquire SOMATEX, Leader in Biopsy Site Markers and Localization Technologies, for $64 Million
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, announced today it has completed the acquisition of SOMATEX Medical Technologies GmbH, a leader in biopsy site markers and localization technologies, for approximately $64 million. The company was previously owned by E-Med Solutions GmbH, Berlin, a group of investors led by German private equity company Westlake Partners.
Dec 28, 2020 04:02 pm ET
Hologic to Webcast Presentation at the 39th Annual J.P. Morgan Healthcare Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 11:40 a.m. Eastern Time.
Dec 01, 2020 08:05 am ET
Hologic Receives FDA Clearance for Latest Breakthrough in Early Breast Cancer Detection, Genius AI™ Detection
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, today announced U.S. Food and Drug Administration (FDA) clearance and commercial availability of the Company’s Genius AI™ Detection technology, a new deep learning-based software designed to help radiologists detect subtle potential cancers in breast tomosynthesis images.
Nov 27, 2020 08:08 am ET
Hologic to Showcase Products Across Breast Cancer Screening, Biopsy, Surgery and Treatment at Virtual RSNA 2020
Hologic, Inc. (Nasdaq: HOLX) will virtually showcase its extensive portfolio of breast and skeletal health products, including screening, surgical, interventional, ultrasound and skeletal solutions, at the 106th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 29 to Dec. 5.
Nov 25, 2020 08:30 am ET
Hologic to Webcast Presentation at Upcoming Virtual Investor Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 3rd Annual Evercore ISI HealthCONx Conference on Wednesday, December 2 at 4:20 p.m. Eastern Time.
Nov 20, 2020 08:08 am ET
Aptima HIV-1 Quant Dx Assay Receives Additional FDA Approval for Use as an Aid in the Diagnosis of HIV Infection
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has approved a diagnostic claim for its HIV-1 (human immunodeficiency virus type 1) viral load monitoring assay. The Aptima® HIV-1 Quant Dx assay is now the first dual-claim assay for both diagnosis and viral load monitoring in the United States.
Nov 17, 2020 02:00 am ET
Hologic Announces CE Mark of the Genius™ Digital Diagnostics System for Cervical Cancer Screening
Hologic, Inc. (Nasdaq: HOLX) announced today that its new Genius™ Digital Diagnostics System is now CE marked in Europe. Genius Digital Diagnostics is the first digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced digital imaging to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.
Nov 04, 2020 04:01 pm ET
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2020
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 26, 2020.
Oct 30, 2020 05:56 pm ET
Hologic Awarded U.S. Government Contract to Expand COVID-19 Test Production Capacity
Hologic, Inc. (Nasdaq: HOLX) announced today that it has been awarded a $119 million contract from the United States government to expand its production capacity for COVID-19 molecular tests. The contract will support capital and labor investments enabling Hologic to provide 13 million COVID-19 tests per month for the U.S. market by January of 2022.
Oct 26, 2020 08:00 am ET
Hologic Launches 3DQuorum™ Imaging Technology, Powered by Genius AI™, in Europe
Hologic, Inc. (Nasdaq: HOLX) today announced the commercial availability in Europe of its 3DQuorum™ Imaging Technology, Powered by Genius AI™. The innovation was designed to help improve mammography efficiency and workflow, which is critical as clinics strive to manage the backlog of women whose routine breast screening was delayed due to the COVID-19 lockdown.
Oct 07, 2020 04:04 pm ET
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2020 on Wednesday, November 4, 2020
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2020 on Wednesday, November 4, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Oct 06, 2020 04:03 pm ET
FDA Amends Emergency Use Authorization for Hologic’s Aptima SARS-CoV-2 Assay to Include COVID-19 Testing of Asymptomatic Individuals, Symptomatic Sample Pooling
Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® SARS-CoV-2 assay, which initially received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in May, is now authorized for testing of individuals without symptoms or other reasons to suspect COVID-19 infection.
Oct 01, 2020 04:02 pm ET
Hologic Announces Multi-Year, Multi-Pronged Commitment to Tackling Breast Cancer Screening Disparities for Black Women in Partnership with the Black Women’s Health Imperative and RAD-AID
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, today announced a multi-year commitment to decreasing breast cancer screening disparities for Black women.
Sep 28, 2020 08:00 am ET
Hologic Granted FDA Emergency Use Authorization for Asymptomatic COVID-19 Testing with Panther Fusion SARS-CoV-2 Assay
Hologic, Inc. (Nasdaq: HOLX) announced today that its Panther Fusion® SARS-CoV-2 assay has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for testing of individuals without symptoms or other reasons to suspect COVID-19 infection.
Sep 14, 2020 06:52 pm ET
Hologic Announces Pricing of Offering of $950 Million of 3.250% Senior Notes Due 2029
Hologic, Inc. (Nasdaq: HOLX) announced today that it has priced its previously announced private offering of $950 million aggregate principal amount of 3.250% senior notes due 2029 at an issue price of $1,000 per $1,000. The 2029 notes will be unsecured obligations of the Company and will be guaranteed by certain subsidiaries. The offering is expected to close on September 28, 2020, subject to customary closing conditions.
Sep 14, 2020 08:01 am ET
Hologic Announces Offering of $950 Million of Senior Notes Due 2029
Hologic, Inc. (Nasdaq: HOLX) announced today that it has launched, subject to market and other conditions, a private offering of $950 million aggregate principal amount of senior notes due 2029. Hologic intends to use the proceeds of the offering and available cash to refinance its existing 4.375% senior unsecured notes due 2025 (the 2025 notes), and will use current cash to pay transaction-related premiums, fees and expenses.
Sep 14, 2020 03:00 am ET
Aptima® HIV-1 Quant Dx Assay Awarded WHO Prequalification for Dried Blood Spot Samples
Hologic, Inc. (Nasdaq: HOLX) announced today that its CE-marked Aptima® HIV-1 Quant Dx assay has been awarded World Health Organization (WHO) prequalification for testing of dried blood spot (DBS) samples.
Sep 04, 2020 04:02 pm ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming virtual investor conferences:
Aug 25, 2020 04:02 pm ET
Hologic to Acquire Acessa Health, Innovator in Minimally Invasive Solutions for Treatment of Fibroids
Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has acquired Acessa Health Inc., a privately-held innovator in minimally invasive treatment for fibroids, for approximately $80 million in cash plus contingent payments based on future revenue growth.
Aug 11, 2020 08:02 am ET
Hologic Launches Validated Pooling Protocol for COVID-19 Testing
Hologic, Inc. (Nasdaq: HOLX) announced today that it has validated use of its Aptima® and Panther Fusion® molecular diagnostic COVID-19 assays with pooled patient samples and completed an emergency use notification to the U.S. Food and Drug Administration (FDA) to make this workflow available to laboratory customers in the United States. By allowing samples from multiple individuals to be tested simultaneously, pooling is expected to help laboratories deliver increasing numbers of highly accurate molecular test results more quickly.
Aug 03, 2020 08:08 am ET
Hologic Announces ‘Back to Screening’ Campaign Encouraging Women to Prioritize Mammograms Delayed due to COVID-19 Pandemic
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company, today launched the Back to Screening campaign encouraging women to schedule their annual mammograms now that healthcare facilities across the nation are re-opening their doors following closures due to the COVID-19 pandemic.
Jul 31, 2020 08:00 am ET
New Cervical Cancer Screening Guidelines from the American Cancer Society Risk Reversing Decades of Progress Made Against Cervical Cancer
Hologic, Inc. (Nasdaq: HOLX) is disappointed that the American Cancer Society (ACS) has released guidelines for cervical cancer screening that significantly diverge from those of other leading medical and governmental institutions, including the American College of Obstetricians and Gynecologists (ACOG), the United States Preventive Services Task Force (USPSTF) and the Women’s Preventive Services Initiative (WPSI). By moving toward limiting options for women and overlooking critical data that supports time-tested screening strategies, the ACS now stands alone as an outlier among these organiza
Jul 29, 2020 04:01 pm ET
Hologic Announces Financial Results for Third Quarter of Fiscal 2020
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 27, 2020.
Jul 08, 2020 08:08 am ET
Hologic Launches its First Cart-Based Ultrasound System, SuperSonic™ MACH 40
Hologic, Inc. (Nasdaq: HOLX) announced today the U.S. launch of the SuperSonic™ MACH 40 ultrasound system, expanding the Company’s suite of ultrasound technologies with its first premium, cart-based system. The new system features excellent image quality, standard-setting imaging modes, and is designed to enhance efficiency and accuracy.
Jul 02, 2020 08:15 am ET
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2020 on Wednesday, July 29, 2020
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2020 on Wednesday, July 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Jun 01, 2020 04:05 pm ET
Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming virtual investor conferences:
May 15, 2020 08:01 am ET
Hologic Granted FDA Emergency Use Authorization for Its Second Molecular Test for COVID-19
Hologic, Inc. (Nasdaq: HOLX) announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its Aptima SARS-CoV-2 assay to detect the novel coronavirus.
May 06, 2020 08:15 am ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming virtual investor conferences:
Apr 29, 2020 04:01 pm ET
Hologic Announces Financial Results for Second Quarter of Fiscal 2020
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 28, 2020.
Apr 29, 2020 04:01 pm ET
Hologic to Introduce Its Second High-Throughput Molecular Assay for the Novel Coronavirus (SARS-CoV-2)
Hologic, Inc. (Nasdaq: HOLX) announced today that it plans to launch a new Aptima® molecular assay to detect the SARS-CoV-2 virus that will run on its market-leading Panther® system. Combining significant manufacturing capacity for the new test with the world’s largest installed base of high-throughput molecular instruments is expected to dramatically increase testing capabilities for the novel coronavirus.
Apr 07, 2020 08:05 am ET
Hologic to Announce Financial Results for the Second Quarter of Fiscal 2020 on Wednesday, April 29, 2020
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2020 on Wednesday, April 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Apr 07, 2020 07:30 am ET
Hologic Announces Preliminary Revenue Results for Second Quarter of Fiscal 2020, Withdraws 2020 Financial Guidance due to COVID-19 Pandemic
Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its second fiscal quarter ended March 28, 2020, and withdrew its 2020 financial guidance due to the uncertain economic impact of the COVID-19 pandemic.
Mar 16, 2020 07:54 pm ET
Hologic’s Molecular Test for the Novel Coronavirus, SARS-CoV-2, Receives FDA Emergency Use Authorization
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the Company’s new Panther Fusion® SARS-CoV-2 assay, a molecular diagnostic test that detects SARS-CoV-2, the virus that causes COVID-19 disease.
Mar 12, 2020 08:08 am ET
Hologic Places 1,000th Panther Molecular Diagnostics System in the United States
Hologic (Nasdaq: HOLX) announced today the 1,000th placement of a Panther system, the Company’s market-leading automated molecular instrument, in a United States diagnostics laboratory. The 1,000th Panther was unveiled today at PathGroup, one of the largest private providers of comprehensive anatomic, clinical and molecular pathology laboratory services in the country. Founded in 1965 and based in Nashville, PathGroup delivers premier diagnostic serves to over 15,000 physician clients, hospitals and surgery centers across the United States.
Mar 05, 2020 02:00 am ET
German Lab Demonstrates Feasibility to Detect SARS-Coronavirus-2 (SARS-CoV-2) Using Hologic’s Panther Fusion® System
A molecular assay for detecting the novel coronavirus SARS-CoV-2 (previously 2019-nCoV) on the automated Panther Fusion® system has been developed by investigators at Hannover Medical School in Germany, Hologic (Nasdaq: HOLX) announced today. The preclinical assay is described online in the
Feb 18, 2020 05:02 pm ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming investor conferences:
Feb 05, 2020 08:08 am ET
Hologic Launches New Scalable Options for Panther System in the United States and Europe
New product offerings within the Panther Scalable Solutions (PSS) portfolio are now commercially available in the United States and Europe, Hologic (Nasdaq: HOLX) announced today. These new optional configurations, which represent Hologic’s next generation of molecular diagnostics innovation, will allow laboratories to scale their instrumentation to meet testing demands in both their current workflow and their future growth plans.
Jan 29, 2020 04:02 pm ET
Hologic Announces Financial Results for First Quarter of Fiscal 2020
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 28, 2019.
Jan 22, 2020 04:05 pm ET
Hologic’s First Sustainability Report Highlights Global Corporate Citizenship Efforts in Fiscal 2019
Hologic, Inc. (Nasdaq: HOLX) announced today the release of the Company’s first sustainability report, Making a Unique Difference in the World. In the report, the Company highlights its global corporate citizenship efforts around the key environmental, social and governance areas that are important to the company’s investors, employees, customers and other stakeholders.
Jan 12, 2020 05:00 pm ET
Hologic Announces Preliminary Financial Results for First Quarter of Fiscal 2020
Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 28, 2019.
Jan 07, 2020 08:22 am ET
Hologic to Announce Financial Results for the First Quarter of Fiscal 2020 on Wednesday, January 29, 2020
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2020 on Wednesday, January 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Dec 31, 2019 08:30 am ET
Hologic to Webcast Presentation at the 38th Annual J.P. Morgan Healthcare Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13 at 8 a.m. Pacific Time.
Dec 30, 2019 09:24 am ET
Hologic Completes Divestiture of Cynosure Medical Aesthetics Business
Hologic, Inc. (Nasdaq: HOLX) announced today that it has completed the previously announced divestiture of its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayto
Dec 02, 2019 07:00 am ET
Women’s Healthcare Leader Hologic to Showcase Comprehensive Portfolio of Breast and Skeletal Health Solutions at RSNA 2019
Hologic, Inc. (Nasdaq: HOLX) will showcase its comprehensive portfolio of breast and skeletal health products, including screening, interventional, surgical, ultrasound and skeletal solutions, in Booth #2511 at the 105th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) at McCormick Place in Chicago from Dec. 1 to 5.
Nov 27, 2019 08:22 am ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming investor conferences:
Nov 25, 2019 08:22 am ET
Newly Published Research Shows that Hologic’s Molecular Assays for Diagnosing Vaginitis are More Effective than Traditional Methods
Clinical evidence demonstrating the effectiveness of new FDA-cleared assays for the detection of vaginitis has been published online in the Journal of Clinical Microbiology. The prospective, multi-center clinical study is the first in the United States to formally validate the performance of the Aptima® BV and Aptima® CV/TV assays, available from Hologic, Inc. (Nasdaq: HOLX) on its fully automated Panther® system.
Nov 20, 2019 07:30 am ET
Hologic to Sell Cynosure Medical Aesthetics Business to Clayton, Dubilier & Rice
Hologic, Inc. (Nasdaq: HOLX) announced today that it has entered into a definitive agreement to sell its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice for a total purchase price of $205 million in cash, subject to certain closing adjustments. Net of these adjustments, Hologic expects net cash proceeds of approximately $138 million.
Nov 12, 2019 08:15 am ET
Hologic Announces FDA Approval of 3DQuorum™ Imaging Technology, Powered by Genius AI™
Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has approved 3DQuorum™ Imaging Technology, powered by Genius AI™. 3DQuorum technology works in tandem with Hologic’s Clarity HD™ high resolution imaging technology to reduce tomosynthesis image volume for radiologists by 66 percent.2
Nov 11, 2019 08:10 am ET
Newly Published Research Demonstrates Ability of Hologic’s Assay to Detect Mycoplasma Genitalium, “the Silent Epidemic”
A newly published study demonstrates clinical evidence for the effectiveness of a first-of-its-kind, FDA-cleared assay for the detection of the sexually transmitted bacterium Mycoplasma genitalium (M. genitalium). Published in the November issue of the Journal of Clinical Microbiology, the prospective, multi-center Aptima Mycoplasma genitalium Evaluation Study (AMES) is the first clinical study to validate the performance of Hologic’s (Nasdaq: HOLX) Aptima® Mycoplasma genitalium assay in the United States.1
Nov 06, 2019 04:01 pm ET
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2019
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal fourth quarter ended September 28, 2019.
Nov 04, 2019 04:05 pm ET
Hologic Launches Definity Cervical Dilator to Provide Gentle and Seamless Dilation During Gynecologic Procedures
Hologic, Inc. (Nasdaq: HOLX) has launched the Definity™ cervical dilator, a major advancement for gynecological procedures that uses SureAccess™ balloon technology to gently and effortlessly access uterine cavities without a tenaculum, lessening patient discomfort and reducing risk of perforation during dilation.1-3
Oct 29, 2019 03:00 am ET
Cynosure Extends Body Contouring Portfolio with Launch of StimSure® in Europe
Cynosure, a division of Hologic, has launched StimSure®, a non-invasive electromagnetic technology to build and tone muscle in the abdomen, buttocks and thighs, in Europe and the Middle East. This new addition to Cynosure’s body portfolio joins SculpSure® and TempSure® to enable customers to offer a full body solution.
Oct 24, 2019 04:21 pm ET
USA Today Article Confuses Patients on Benefits of 3D Mammography for Breast Cancer Screening
Hologic, Inc. (Nasdaq: HOLX) today objected to the October 24, 2019 USA Today article, “3D mammograms getting the hard sell,” and reaffirmed its position that breast cancer screening with 3D mammography offers women the best chance of early diagnosis.
Oct 14, 2019 10:13 am ET
No More Excuses: There is Now a More Comfortable Mammogram
MARLBOROUGH, Mass., Oct. 14, 2019 /PRNewswire/ --
Oct 10, 2019 04:05 pm ET
Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2019 on Wednesday, November 6, 2019
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2019 on Wednesday, November 6, 2019, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Oct 08, 2019 12:00 pm ET
SuperSonic Imagine Unveils Its Latest Innovations at the French Days of Radiology (JFR) 
SuperSonic Imagine (Euronext: SSI, FR0010526814), a company specialising in medical ultrasound imaging, is expanding its product range and will for the first time present a suite of new ultrasound markers1 alongside its new ultrasound platform,...
Oct 01, 2019 08:08 am ET
Hologic CEO Steve MacMillan to Ring Nasdaq Opening Bell on October 2
Hologic, Inc. (Nasdaq: HOLX) announced today that Steve MacMillan, the Company’s Chairman, President and Chief Executive Officer, will join a number of employees to ring the Nasdaq Opening Bell for the 14th consecutive year on October 2 to mark the start of Breast Cancer Awareness Month.
Sep 04, 2019 04:02 pm ET
Hologic to Webcast Presentation at the Morgan Stanley 17th Annual Global Healthcare Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Morgan Stanley 17th Annual Global Healthcare Conference in New York, NY on Tuesday, September 10 at 12:20 p.m. Eastern Time.
Aug 01, 2019 04:09 pm ET
Hologic Acquires Approximately 46% of Shares in SuperSonic Imagine, a French Innovator in Ultrasound Medical Imaging
Hologic, Inc. (Nasdaq : HOLX), a global leader in women’s health, and SuperSonic Imagine (Euronext: SSI, FR0010526814), a company specialized in ultrasound medical imaging, jointly announce today that Hologic Hub Ltd, a wholly-owned indirect subsidiary of Hologic, Inc., has acquired approximately 46% of SuperSonic Imagine shares, pursuant to a shares sale agreement entered into today.
Aug 01, 2019 04:05 pm ET
Hologic to Webcast Presentation at the Canaccord Genuity 39th Annual Growth Conference
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Canaccord Genuity 39th Annual Growth Conference in New York, NY on Wednesday, August 7 at 10 a.m. Eastern Time.
Jul 31, 2019 04:01 pm ET
Hologic Announces Financial Results for Third Quarter of Fiscal 2019
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 29, 2019.
Jul 26, 2019 08:08 am ET
Hologic's Cynosure Division Expands Body Contouring Portfolio with TempSure® Firm for Tissue Heating and Cellulite Treatments and SculpSure® Petite Mask for Submental Fat Reduction
Hologic’s (Nasdaq: HOLX) Cynosure division announced today the launch of two new products that expand the Company’s growing portfolio of innovative aesthetic treatments — the TempSure® Firm handpiece and a petite mask for SculpSure® submental treatments. SculpSure submental treatments are now cleared by the U.S. Food and Drug Administration (FDA) for
Jul 02, 2019 04:05 pm ET
Hologic to Announce Financial Results for the Third Quarter of Fiscal 2019 on Wednesday, July 31, 2019
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2019 on Wednesday, July 31, 2019, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.
Jun 20, 2019 04:01 pm ET
Hologic Enters into Exclusive Negotiations to Acquire SuperSonic Imagine, French Ultrasound Innovator
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has made a binding offer to acquire (directly or through an affiliate) SuperSonic Imagine (Euronext: SSI, FR0010526814), a France-based innovator in cart-based ultrasound products, and that it has entered into an exclusive negotiation agreement with the company and its main shareholders toward that end.
Jun 13, 2019 08:08 am ET
Hologic Receives Manufacturing Leadership Awards for Operational Excellence and Sustainability
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company has been recognized by the National Association of Manufacturers (NAM), the largest manufacturing association in the United States, with Manufacturing Leadership awards for operational excellence and sustainability leadership. The awards were presented at the Manufacturing Leadership Awards Gala and Leadership Summit this week in Huntington Beach, CA.
May 30, 2019 08:30 am ET
Hologic Partners with DEXA+ to Distribute Body Composition Measurement System
Hologic, Inc. (Nasdaq: HOLX) announced today that it has signed an agreement with DEXA+ to distribute Hologic’s Horizon® DXA system for body composition measurement.
May 29, 2019 08:08 am ET
FDA Clearance of Aptima BV and Aptima CV/TV Molecular Assays Ushers in New Era of Comprehensive and Objective Diagnostic Testing for Vaginitis
Hologic, Inc. (Nasdaq: HOLX) announced today that the FDA has granted clearance for its new Aptima® BV and Aptima® CV/TV assays, which provide an accurate and objective method for diagnosing vaginitis, a very common and complex health issue affecting millions of women each year.
May 28, 2019 08:15 am ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming investor conferences:
May 07, 2019 08:20 am ET
Hologic to Webcast Presentations at Upcoming Investor Conferences
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at these upcoming investor conferences:
May 02, 2019 08:12 am ET
Hologic Showcases Growing Portfolio of Women’s Health Products at 2019 American College of Obstetricians and Gynecologists Annual Clinical and Scientific Meeting
Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women's health and well-being, will showcase its comprehensive portfolio of healthcare solutions at the 67th Annual American College of Obstetricians and Gynecologists (ACOG) Clinical and Scientific Meeting. The meeting takes place in Nashville, Tennessee, from May 3 to 6.
May 01, 2019 04:02 pm ET
Hologic Announces Financial Results for Second Quarter of Fiscal 2019
Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 30, 2019.
Apr 30, 2019 08:10 am ET
Hologic Showcases New Breast Surgery Franchise at 20th Annual Meeting of The American Society of Breast Surgeons
Hologic, Inc. (Nasdaq: HOLX) will showcase its growing breast surgery franchise, which includes products such as the new Trident® HD specimen radiography system, LOCalizer™ wire-free guidance system and the BioZorb® marker, in Booth #103 at the 20th Annual Meeting of The American Society of Breast Surgeons (ASBS) in Dallas from April 30 to May 5.
Apr 25, 2019 08:15 am ET
Hologic Launches Trident® HD Specimen Radiography System in United States, Canada and Europe
Hologic, Inc. (Nasdaq: HOLX) today announced global commercial availability of the Trident® HD specimen radiography system, a next-generation solution that delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.1
Apr 23, 2019 08:30 am ET
Hologic’s Cynosure Division Announces Brooke Shields as Celebrity Spokesperson for SculpSure® Body Contouring
Hologic’s (Nasdaq: HOLX) Cynosure division announced today that iconic actress, model, Broadway star and author Brooke Shields will serve as national spokesperson for the state-of-the-art SculpSure® body contouring laser treatment. As the face of SculpSure’s new “Be strong. Be sexy. Be confident.” campaign, Shields will insp
Apr 18, 2019 03:00 am ET
Hologic Receives European CE Mark for ThinPrep® Genesis Processor, an Automated Cytology Slide and Molecular Sample System
Hologic, Inc. (Nasdaq: HOLX) announced today that the ThinPrep® Genesis processor for cytology slide and molecular test preparation has received a CE IVD mark in Europe. The system features increased automation capabilities, together with ergonomic and chain of custody benefits, compared to older instruments. Most importantly, the instrument will prepare slides for cytology as well as aliquot samples for molecular testing, reducing manual sample handling.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.